| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Soiken Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥122.00 |
| 52 Week High | JP¥293.00 |
| 52 Week Low | JP¥107.00 |
| Beta | -0.0027 |
| 11 Month Change | -27.38% |
| 3 Month Change | -29.07% |
| 1 Year Change | -55.96% |
| 33 Year Change | -68.06% |
| 5 Year Change | -80.42% |
| Change since IPO | -96.19% |
Recent News & Updates
Many Still Looking Away From Soiken Holdings Inc. (TSE:2385)
Aug 02
A Piece Of The Puzzle Missing From Soiken Holdings Inc.'s (TSE:2385) Share Price
Apr 01Shareholder Returns
| 2385 | JP Personal Products | JP Market | |
|---|---|---|---|
| 7D | -29.1% | -5.7% | -11.1% |
| 1Y | -56.0% | -11.0% | 4.7% |
Return vs Industry: 2385 underperformed the JP Personal Products industry which returned -15% over the past year.
Return vs Market: 2385 underperformed the JP Market which returned -3.7% over the past year.
Price Volatility
| 2385 volatility | |
|---|---|
| 2385 Average Weekly Movement | 9.0% |
| Personal Products Industry Average Movement | 5.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in JP Market | 9.7% |
| 10% least volatile stocks in JP Market | 3.2% |
Stable Share Price: 2385's share price has been volatile over the past 3 months.
Volatility Over Time: 2385's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 98 | Kentaro Ishigami | www.soiken.com |
Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes.
Soiken Holdings Inc. Fundamentals Summary
| 2385 fundamental statistics | |
|---|---|
| Market cap | JP¥3.19b |
| Earnings (TTM) | -JP¥619.00m |
| Revenue (TTM) | JP¥5.33b |
0.6x
P/S Ratio-5.2x
P/E RatioIs 2385 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2385 income statement (TTM) | |
|---|---|
| Revenue | JP¥5.33b |
| Cost of Revenue | JP¥2.84b |
| Gross Profit | JP¥2.49b |
| Other Expenses | JP¥3.11b |
| Earnings | -JP¥619.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | -23.66 |
| Gross Margin | 46.76% |
| Net Profit Margin | -11.60% |
| Debt/Equity Ratio | 0% |
How did 2385 perform over the long term?
See historical performance and comparison